Skip to content
DataLookout
Menu

CATTALYSTNCT07710716

A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 1 year 9 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Sep 30, 2026 to Jun 30, 2028
    • Primary endpoints: details revised at 1 of 17 entries
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 8 of 45 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Cohort B and Subcohort B1: Proportion of Patients by Baseline Demographics and Clinical Characteristics
Timeframe: Baseline
Cohort B and Subcohort B1: Proportion of Patients by Demographics and Clinical Characteristics at Index Treatment Date
Timeframe: Baseline
Cohort B and Subcohort B1: Charlson Comorbidity Index (CCI)
Timeframe: Baseline
Cohort B and Subcohort B1: AST Levels at Index Diagnosis Date and Index Treatment Date
Timeframe: Baseline
Cohort B and Subcohort B1: ALT Levels at Index Diagnosis Date and Index Treatment Date
Timeframe: Baseline
Cohort B and Subcohort B1: Total Bilirubin Level at Index Diagnosis Date and Index Treatment Date
Timeframe: Baseline
Cohort B and Subcohort B1: QTc Interval at Index Diagnosis Date and Index Treatment Date
Timeframe: Baseline
Cohort B and Subcohort B1: Neutrophil Count at Index Diagnosis Date and Index Treatment Date
Timeframe: Baseline
Cohort B and Subcohort B1: Duration Between Initial Diagnosis and Ribociclib Initiation
Timeframe: Up to 40 months
Cohort B and Subcohort B1: Duration Between Initial Diagnosis and Surgery
Timeframe: Up to 40 months
Cohort B and Subcohort B1: Duration Between Surgery and Ribociclib Initiation
Timeframe: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients by Type of Surgery Prior to Ribociclib Initiation
Timeframe: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients by Type of BC Treatment Prior to Ribociclib Initiation
Timeframe: Up to 40 months
Cohort B and Subcohort B1: Duration of Neoadjuvant and Adjuvant Therapy by Type, Prior to Ribociclib Initiation
Timeframe: Up to 40 months
Cohort B and Subcohort B1: Proportion of Patients by Year of ET Initiation, Prior to Ribociclib Initiation
Timeframe: Up to 40 months
Cohort B and Subcohort B1: Duration of ET by Type, Prior to Ribociclib Initiation
Timeframe: Up to 40 months
Cohort B and Subcohort B1: Duration of Other Cyclin-dependent Kinase 4/6 Inhibitor (CDK4/6i) Treatment by Type, Prior to Ribociclib Initiation
Timeframe: Up to 40 months

Secondary (45)

Cohort A: Proportion of Patients by Baseline Demographics and Clinical Characteristics
Cohort A: CCI
Cohort A: Duration Between Initial Diagnosis and Surgery
Cohort A: Proportion of Patients by Type of Surgery
Cohort A: Proportion of Patients by Type of BC Treatment Received
Show 40 moreShow less
Cohort A: Duration of Neoadjuvant and Adjuvant Therapy by Type
Cohort A: Proportion of Patients by Year of ET Initiation
Cohort A: Duration of ET by Type
Cohort A: Duration of Other CDK4/6i Treatment by Type
Cohort A: Proportion of Patients by Type of Concomitant Medication Received
Cohort B and Subcohort B1: Proportion of Patients Who Switch to an Alternative CDK4/6i
Cohort B and Subcohort B1: Proportion of Patients Who Receive Concomitant Systemic and Local Oncology Therapies
Cohort B and Subcohort B1: Proportion of Patients Who Receive Subsequent Systemic and Local Oncology Therapies Administered After Ribociclib Initiation
Cohort B and Subcohort B1: Duration of Subsequent Systemic and Local Oncology Therapies Administered After Ribociclib Initiation, by Type of Therapy
Cohort B and Subcohort B1: Time Between Discontinuation of Ribociclib and Start of Subsequent Systemic and Local Oncology Therapies, by Type of Therapy
Cohort B and Subcohort B1: Initial Dose of Ribociclib
Cohort B and Subcohort B1: Proportion of Patients Who Undergo Ribociclib Dose Reduction
Cohort B and Subcohort B1: Time to First Ribociclib Dose Reduction
Cohort B and Subcohort B1: Proportion of Patients by Reason for Ribociclib Dose Reduction
Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Interruptions per Patient Prior to Ribociclib Dose Reduction
Cohort B and Subcohort B1: Proportion of Patients Who Experience Ribociclib Dose Interruption
Cohort B and Subcohort B1: Time to First Ribociclib Dose Interruption
Cohort B and Subcohort B1: Proportion of Patients by Reason for Ribociclib Dose Interruption
Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Reductions per Patient Prior to Ribociclib Dose Interruption
Cohort B and Subcohort B1: Proportion of Patients Who Discontinue Ribociclib Treatment
Cohort B and Subcohort B1: Time-to-Discontinuation (TTD) of Ribociclib Treatment
Cohort B and Subcohort B1: Proportion of Patients by Reason for Ribociclib Discontinuation
Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Interruptions per Patient Prior to Ribociclib Discontinuation
Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Reductions per Patient Prior to Ribociclib Discontinuation
Cohort B and Subcohort B1: Persistence of Ribociclib Treatment
Cohort B and Subcohort B1: Number of Clinical Visits and/or Laboratory Assessments for Ribociclib Monitoring
Cohort B and Subcohort B1: Cumulative Exposure to Ribociclib
Subcohort B1: Incidence of Adverse Events (AEs) of Interest
Subcohort B1: Proportion of Patients Requiring Changes to the Ribociclib Regimen Following AE Occurrence
Subcohort B1: Proportion of Patients by the Sequalae of AEs
Cohort B and Subcohort B1: Proportion of Patients Undergoing Drug-drug Interaction (DDI) Assessment Upon Ribociclib Initiation
Cohort B and Subcohort B1: Proportion of Patients With Actual DDIs
Cohort B and Subcohort B1: Number of DDIs per Patient
Cohort A: Proportion of Patients With Potential DDIs
Cohort B and Subcohort B1: Proportion of Patients With Potential DDIs
Cohort B and Subcohort B1: Proportion of Patients With Potential DDIs Who Experience AEs
Cohort B and Subcohort B1: Proportion of Patients by Clinical Monitoring Practices Before and After DDI Occurrence
Cohort B and Subcohort B1: Among Patients With Clinically Consequential DDIs, Number of Patients by Demographics and Clinical Characteristics
Cohort B and Subcohort B1: Among Patients With Clinically Consequential DDIs, Number of Patients by BC Treatment Prior to Ribociclib
Cohort B and Subcohort B1: Frequency of Ribociclib Treatment Modifications Related to DDIs

Arms and interventions

Cohort A: Contemporaneous Ribociclib-eligible Patients

Adult HR+/HER2- eBC patients who have undergone surgical resection of the primary breast tumor and initiated adjuvant ET and meet additional staging criteria including either Stage III, or Stage IIB, or Stage IIA with N1, Stage IIA with N0 and Grade 3, or Stage IIA with N0 and Grade 2 and Ki-67 ≥20% or high genomic risk.

Cohort B: Ribociclib-treated Patients

Adult HR+/HER2- eBC patients who have undergone surgical resection of the primary breast tumor and initiated adjuvant ribociclib in addition to ET.

Subcohort B1: Ribociclib-treated Subcohort for Landmark Safety Analysis

Patients in Cohort B who have at least six months of potential follow-up time after ribociclib initiation at the time of the analysis.

Sites

1 site in 1 country

  • NovartisBasel, Switzerland